• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

    Gabrielle Lakusta
    Mar. 19, 2018 03:59PM PST
    Pharmaceutical Investing

    Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced its fourth quarter and full year 2017 financial results and business highlights. As quoted in the press release: “In 2017 we made significant progress across our clinical programs and successfully completed our initial public …

    Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced its fourth quarter and full year 2017 financial results and business highlights.

    As quoted in the press release:

    “In 2017 we made significant progress across our clinical programs and successfully completed our initial public offering. This momentum has continued into 2018, with the recently announced 18-month data from the Phase 2 FILLY trial in patients with GA reinforcing the statistically significant effect seen at 12 months and supporting our plans to move to Phase 3 in the second half of this year,” said Cedric Francois, MD, PhD, founder and chief executive officer of Apellis. “We plan to advance APL-2 in multiple indications throughout the upcoming year, including initiating Phase 3 trials in GA and PNH, Phase 2 proof-of-concept data readouts in AIHA and CDN, and data readouts in our Phase 1b eculizumab add-on and monotherapy expansion studies in PNH. We believe that APL-2 and our core focus of targeting the complement pathway centrally at the level of C3 has the potential to help patients with unmet needs in these indications, and in a broad variety of other complement-mediated conditions.”

    Click here to read the full press release.

    pharmaceutical investingpublic offeringclinical-stage biopharmaceuticalfinancial resultsinitial public offeringclinical-stage biopharmaceutical company
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts are in the background.

    Top 5 NASDAQ Pharma Stocks (Updated July 2024)

    PLx Pharma Reports Fourth Quarter and Full Year 2017 Results

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×